Table 1 Clinical studies of SCIT/SLIT efficacy in AD
From: Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis
Authors | Year of research | Country | Study design | The number of patients (treatment/control) | Category of the patients (Age) | The type of allergen | Route of administration | The total duration of the study (in months) | Clinical efficacy (the opinion of the Clinician -C/patient-P) Treatment/control (in %) | Reference number |
|---|---|---|---|---|---|---|---|---|---|---|
Kaufman H.S., Roth H.L. | 1974 | US | qRCT DB PC | 52 (26/26) | children/adults (2–47) | animal dander, HDM molds, pollen | SCIT | 24 | C(+) | 45 |
81,3/40 | ||||||||||
Warner J.O. et al. | 1978 | UK | RCT DB PC | 20 (9/11) | children (5–14) | HDM | SCIT | 12 | P(+) | 92 |
77,8/27,3 | ||||||||||
Ring J. | 1982 | Germany | RCT DB PC | 2 (1/1) | children (10) | Grass pollen | SCIT | 24 | C(+) | 71 |
SCORAD improvement from score 30→10/26→21 | ||||||||||
Glover M.T., Atherton D.J. | 1992 | UK | RCT DB PC | 24 (13/11) | children (5–16) | HDM | SCIT | 8 -13,5 | P(+) | 39 |
61,5/81,8 | ||||||||||
Galli E. et al. | 1994 | Italy | RCT DB PC | 60 (NM) | children (0,5-12) | HDM | SCIT | Till 36 (mean duration 18.7) | C(+) | 38 |
Group A (AD+AR/BA)/Group B&Group C (AD) Improvement of skin lesions: 81/63/61 | ||||||||||
Silny M., Czarnecka- Operacz W. | 2006 | Poland | RCT DB PC | 20 (10/10) | children/adults (5–40) | dander, HDM pollen (adsorbed with aluminum hydroxide) | SCIT | 12 | C(+) | 76 |
80/10 on the base of W-АЗС index, specific IgE (р<0,001) | ||||||||||
Silny W. et al. | 2005 | Poland | CT | 68 (36- HDM+ 12-Pollen/20-BT***) | children/teenagers | HDM Pollen | SCIT | 36 | C(+) | 73-75 |
Significant clinical efficacy W-АЗС index > BT (р <0,001) | ||||||||||
Czarnecka- Operacz M, Silny W. | 2006 | Poland | NM | 66 | NM (subgroup with different age) | HDM/grass pollen/grass + mugwort pollen | SCIT | 48 | C(+) | 25 |
Significant clinical efficacy with IgE-mediated airborne allergy | ||||||||||
37(14/17/6)/ 29 | ||||||||||
Bussmann C. et al. | 2006 (2007) | Germany | pilot study (systematic overview) | 25 | NM | HDM | SCIT | 4 | C(+) | 13,14 |
SCORAD, specific IgE, IgG4, IL-10 | ||||||||||
Slavyanskaya T. et al., | 2013-2015 | Russia | CT | 350 | children/teenagers (3–18) | HDM | SCIT | ≥36 | C(+) | 29-35, 77,78, 80-83 |
Derkach V. et al. | 300/50 (moderate-severe AD) | QOL (scores) 11.32→ in 3 times decreased (р<0,001), SCORAD | ||||||||
42,57→5,19, specific IgE, IL-4, IL-10 |